SCHEMBL1310225

SCHEMBL1310225

c1nc2c(N3CCOCC3)nc(-c3ccc4[nH]ncc4c3)nc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.58
PIK3CG P48736 3/20 0.58
PIK3CD O00329 2/20 0.58
GRIA1 P42261 8/20 0.49
CYP2C9 P11712 1/20 0.49
CACNG2 Q9Y698 1/20 0.49
ROCK2 O75116 3/20 0.47
ROCK1 Q13464 2/20 0.47
PKN2 Q16513 2/20 0.47
PKN1 Q16512 1/20 0.47
PRKCH P24723 1/20 0.46
PRKCQ Q04759 1/20 0.46
PIK3CB P42338 2/20 0.45
HDAC1 Q13547 1/20 0.44
MTOR P42345 1/20 0.42
MAP4K4 O95819 1/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK1D P48730 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1309577 0.84 PIK3CA (0.60) PIK3CAPIK3CGPIK3CDGRIA1CYP2C9
SCHEMBL1192544 0.79 PIK3CA (0.72) PIK3CAPIK3CGPIK3CDPIK3CBMTOR
SCHEMBL1309866 0.77 PIK3CA (0.55) PIK3CAPIK3CGPIK3CDGRIA1CYP2C9
SCHEMBL1309993 0.77 PIK3CA (0.57) PIK3CAPIK3CGPIK3CDGRIA1CYP2C9
SCHEMBL1310406 0.76 PIK3CA (0.71) PIK3CAPIK3CGPIK3CDPIK3CBHDAC1
SCHEMBL1192611 0.76 PIK3CA (0.66) PIK3CAPIK3CGPIK3CDPIK3CBMTOR
SCHEMBL1310077 0.73 LMNA (0.55) PIK3CAPIK3CGPIK3CDGRIA1CYP2C9
SCHEMBL1309350 0.73 PIK3CA (0.68) PIK3CAPIK3CGPIK3CDPIK3CBMTOR
SCHEMBL10267840 0.72 PIK3CA (0.64) PIK3CAPIK3CGPIK3CDPIK3CBMTOR
SCHEMBL22085802 0.72 PIK3CA (0.66) PIK3CAPIK3CGPIK3CDGRIA1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
WO-2010052569-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES MTOR, PIK3CA, PIK3CD PIK3CA 2/4885PIK3CG 16/4885PIK3CD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.